1 Central effects of the diuretic, bendrofluazide (2.5, 5 and 10 mg) were studied in 12 healthy volunteers. Two placebos and an active control drug, oxazepam (15 mg), were included. Single doses were administered double-blind at 10.00 h. The effects of drugs on performance and subjective feelings were assessed before and from 1.5-2.5 and 3.5-4.5 h after ingestion, and recordings of the electrical activity of the brain (EEG) and body sway carried out. 2 Performance was assessed using digit symbol substitution, continuous attention, letter cancellation, choice reaction time, finger tapping, immediate and short-term memory, together with critical flicker fusion and two flash fusion. Subjects assessed their mood and well-being on a series of 12 visual analogue scales. The EEG was recorded with eyes open while the subjects carried out a mental arithmetic task, and with eyes closed, when they were required to relax. Body sway was recorded with eyes open and with eyes closed. 3 Bendrofluazide (10 mg) increased the number of errors at letter cancellation and reduced the rate of finger tapping (P < 0.05), while oxazepam increased the number of errors and reduced accuracy at continuous attention (P < 0.01), and increased the number of involuntary rest pauses during tapping (P < 0.05). 4 There were no effects of drugs on subjective assessment of mood. 5 No changes in the electrical activity of the brain were observed with bendrofluazide. In recordings with eyes open, oxazepam reduced delta (0.5-3 Hz), theta (3.5-7 Hz) and alpha 2 (10.5-13 Hz) while increasing beta 1 (13.5-21 Hz) activity. With eyes closed, oxazepam decreased alpha 1 (7.5-10 Hz) and alpha 2 power. These changes were statistically significant at the 5% level or less. 6 Bendrofluazide (2.5 mg) increased the amplitude of body sway in the frequency range 0.05-1.0 Hz (P < 0.05), while oxazepam increased activity in ranges 0.05-1.0 Hz (P < 0.01) and 3.25-4.0 Hz (P < 0.05). 7 There was no evidence for any central effect of the diuretic, bendrofluazide, although adverse changes in psychomotor performance and body sway were apparent. Despite the absence of sedation or reduced vigilance, the effects on performance suggest that diuretics may not be the most appropriate medication for individuals engaged in skilled activity, given the availability of alternative medications such as angiotensin converting enzyme inhibitors that do not impair performance.
Introduction
Mild hypertension affects a significant proportion of the between classes of drug, particularly those that are working population, and there is now a wide range of related to changes in the central nervous system. This drugs available for treatment. However the incidence issue is important, particularly for those individuals and nature of unacceptable side effects varies greatly engaged in skilled employment. Previously we have investigated the major classes of antihypertensive drugs using a comprehensive and standardised range of performance tests and measures of central activity to identify treatments with least adverse effects. Sedation and reduced vigilance were evident with the 0-adrenoceptor antagonists, propranolol and atenolol [1, 2] , while captopril, an angiotensin converting enzyme inhibitor, did not adversely affect central function [3, 4] . The calcium antagonist, nifedipine, modified activity of the central nervous system, although alertness and performance were unaffected [5] . The present study now assesses the central effects of a thiazide diuretic, bendrofluazide, which despite its frequent use particularly in combination with other antihypertensive drugs has not been systematically investigated with regard to changes in central function.
Methods

Subjects and restrictions
The subjects were 12 healthy male volunteers aged between 21 and 35 (mean 26.2) years, weighing between 66 and 97 (mean 74.5) kg, and were students or university employees. The study was approved by the Hospital Ethics Committee, and subjects were required to provide written informed consent. Individuals with a history of asthma, insulin dependent diabetes mellitus or hypertension were excluded from the trial. Similarly, those receiving treatment with sedative, hypnotic, antidepressant or antihypertensive medication were excluded.
During the study, subjects were asked to abstain from alcohol on the evening before each experiment and to retire at their usual bed-time. They were asked to eat a light breakfast before attending the laboratory, and upon arrival were screened to ensure that no alcohol had been consumed. No caffeine-containing beverages were allowed during the day of the study.
Each subject ingested single doses of bendrofluazide (2.5, 5 or 10 mg), and two inactive placebos and an active control drug, oxazepam (15 mg), were included in the study. The drugs were administered double-blind according to a multiple Latin square design, with one placebo included in each half of the design. Treatments were separated by at least 1 week. The drugs were taken orally at 11.00 h, and performance and physiological parameters tested 1 h before (10.00 h) and from 1.5-2.5 h and from 3.5-4.5 h after ingestion. Heart rate and resting blood pressure were recorded during each session. Venous blood was taken during the two post-ingestion sessions, and the samples spun and stored at -20°C until analysis. Plasma bendrofluazide concentrations were evaluated by high-performance liquid chromatography [6] .
Performance testing and physiological procedures
Before the study began, subjects were trained to plateau level on each of the performance tests and were familiarised with the schedule and physiological procedures. On days of the study, each test session lasted approximately 1 h and consisted of several aspects of performance, critical flicker fusion and two-flash fusion, subjective assessment of well-being and recordings of body sway and the waking electroencephalogram (EEG).
Performance and the EEG were recorded in individual cubicles, and critical flicker fusion and twoflash fusion tested in a room with controlled lighting to allow dark adaptation. All measures other than memory were completed on three occasions each day.
Digit symbol substitution test (DSST) Two sheets each containing 200 randomised digits and a code relating each digit to a symbol were presented to the subjects. For each sheet, they were given 2 min to complete as many substitutions as possible, and the total number of substitutions recorded.
Six-letter cancellation Subjects were presented with a single sheet containing 1200 randomised letters arranged in 40 columns, with 6 target letters printed at the top. They were required to cancel as many target letters as possible in 5 min, and the number of letters correctly cancelled, attempted and errors were recorded.
Continuous attention A randomised series of letters generated by microcomputer was presented on individual TV monitors at a rate of one per second, and a 'critical stimulus' consisting of two letters displayed continuously on the screen. Subjects were required to press a key within 750 ms when the second letter followed the first in the random series. The test lasted 15 min, and the number of correct responses and errors were recorded.
Choice reaction time (CRT) Subjects pressed a key corresponding to one of four light emitting diodes illuminated in a random sequence of 30 presentations. Mean reaction time to the last 20 responses was measured.
Short term memory Immediately before drug ingestion, the subjects were presented with a set of twelve photographs of unrelated objects and given 1 min to memorise them. Four hours after drug ingestion they were allowed 45s to recall and write down as many objects as possible.
Immediate and delayed recall memory Two hours after ingestion, immediate recall was tested by presenting a list of 16 unrelated words (two syllable nouns). These were generated by microcomputer and displayed on TV monitors at a rate of one word every 3 s. Immediately after the presentations subjects were allowed 45 s to write down all words recalled. In addition, the subjects were required to recall the word lists 2 h later, corresponding to 4 h after drug ingestion (denoted 'delayed recall' in Results section and Table 1 ).
Finger tapping Subjects tapped a pressure-sensitive transducer as rapidly as possible for 1 min, and the total number of taps and involuntary rest pauses exceeding 250 ms were recorded.
Critical flicker fusion Flicker fusion threshold was measured using a central flickering source, with the initial frequency chosen randomly between 15 and 20 Hz. Frequency then increased or decreased by 4 Hz depending on whether the subject perceived a flickering or fused source. Subsequent changes in response halved the step size until steps of 0.25 Hz were reached. Each stimulus was presented for 2 s and fusion threshold defined as a mean of the last 20 presentations of step size 0.25 Hz.
Two-flash fusion Pairs of 10 ms flashes of light separated by a period between 12 and 120 ms were presented, and the subjects required to report whether the light sources appeared as two separate flashes or were fused. Initial separation was between 50 and 63 ms, with subsequent increases or decreases of 8 ms depending on the subject's response. The step size was then halved until steps of 1 ms were reached. Flash fusion point was defined as a mean of the last 20 responses of 1 ms step size.
Subjective assessments
Subjects assessed their mood and well-being on a series of twelve 100 mm visual analogue scales (0-100) presented on a single sheet, with scores toward 100 representing favourable subjective feelings. The assessments were: A: I am, extremely sleepy (0) -extremely wide awake (100); B: I am, extremely tense (0) -absolutely relaxed (100); C: I am, extremely agitated (0) -absolutely calm (100); D: I am, extremely lethargic (0) -extremely energetic (100); E: I am, mentally very dulled (0) -extremely alert (100); F: I have, no ability to concentrate (0) -complete ability to concentrate (100); G: with regard to carrying out general duties I feel that I am, absolutely useless (0) -extremely efficient (100); H: I am, extremely irritable (0) -not at all irritable (100); I: I am extremely aggressive (0) -extremely passive (100); J: I feel, extremely withdrawn (0) -extremely sociable (100); K: I am, in the depths of depression (0) -ecstatically happy (100); L: I feel, extremely anxious (0) -absolutely carefree (100).
Electroencephalograms
Waking activity was recorded from P3-01 and C3-T3 (10-20 international system), using silversilver chloride electrodes with inter-electrode resistance less than 10 kQ. The EEG was recorded for 2 min with eyes open while the subjects performed a mental arithmetic task, and this was followed by recording 5 min with eyes closed, when the subjects were instructed to relax. The signals were recorded on magnetic cassettes (TDK 60) using ambulatory four-channel Medilog recorders (Oxford Medilog Systems, Model 4-24). 
Statistical analysis
All data were analysed using analysis of variance (ANOVA), with the factors drugs, times and subjects specified in the model. Drugs and times were fixed effects and subjects a random effect. The assumptions of ANOVA -homogeneity of variance, normality and independence -were examined for each variable, and transformations of the data selected where appropriate using the method of maximum likelihood of Box & Cox [7] .
The pre-ingestion sessions were screened for homogeneity, and where no differences were found direct comparisons of mean drug and placebo values after ingestion were made. Where differences at preingestion time occurred, changes from pre-ingestion level were used to compare drug responses with placebo at each post-ingestion time. Based on this criterion, direct comparisons of drugs with placebo were made for all measures other than the EEG, where changes from pre-ingestion time for the drug and placebo treatments were compared.
Single doses of bendrofluazide and the mean response over dose, together with oxazepam were compared with the mean of the two placebos at 2 and 4 h after ingestion, and the response of each drug meaned over post-ingestion sessions estimated. Significance levels for all comparisons were adjusted to allow for multiple simultaneous comparisons using the appropriate Bonferroni bound [8] , and Dunnett's procedure [9] .
Principal components analysis was used to analyse mood assessments, and component scores tested for drug effects using ANOVA and subsequent individual comparisons. Individual assessments were examined but are reported only where additional explanation of effects is provided.
Results
Performance tests
The findings are shown in Table 1 Significance levels: *P < 0.05; **P < 0.01; ***P < 0.001. Standard errors are pooled estimates taken from the analysis of variance based on all treatments.
Electroencephalograms
Recordings with eyes open No changes in the EEG were observed with bendrofluazide. Oxazepam reduced delta activity (P < 0.05) in derivation P3-01 when both post-ingestion sessions were meaned. Theta and alpha 2 activity were reduced (P < 0.05) in C3-T3 2 h after ingestion, accompanied by an increase in beta 1, while theta power decreased (P < 0.01) and beta 1 increased (P < 0.05) 4 h after ingestion. When post-ingestion sessions were meaned, oxazepam decreased theta activity (P < 0.01), while beta 1 was increased (P < 0.01).
Recordings with eyes closed There were no changes in the EEG with bendrofluazide. Oxazepam reduced alpha 1 activity in C3-T3 at both 2 and 4 h after ingestion and when both sessions were meaned (P < 0.001). Alpha 2 activity was decreased 2 h after ingestion and when post-ingestion sessions were meaned (P < 0.001). Similarly, oxazepam decreased total alpha activity 2 h (P < 0.01) and 4 h after ingestion (P < 0.001), and when post-ingestion sessions were meaned (P < 0.001). These findings are shown in Figure 1 .
Body sway
The results are shown in Table 3 . Amplitude of body sway with eyes open in the frequency range 0.05-1 Hz was increased by bendrofluazide (2.5 mg, P < 0.05) and by oxazepam (P < 0.01) when postingestion sessions were meaned.
With eyes closed, no changes occurred with any dose of bendrofluazide, while oxazepam increased 0.05-1 Hz (P < 0.01) and 3.25-4 Hz (P < 0.05) activity when meaned over post-ingestion sessions.
Heart rate and blood pressure Heart rate and both systolic and diastolic blood pressure were unaffected by any of the drugs (Table 4) .
Plasma concentrations
Plasma concentrations for bendrofluazide are shown in Table 5 . Where data have been transformed, standard error is given on the transformed scale.
#square root transform applied to raw data. #log(x -30) applied to raw data. only at the lowest dose. There were however no changes in the EEG, sustained attention, memory or subjective assessment of mood. In contrast, the active control drug oxazepam modified the EEG and impaired sustained attention and finger tapping, whilst also increasing body sway. Despite the known incidence of adverse effects of thiazide diuretics in the patient population [10] including lethargy and fatigue [11, 12] , few systematic studies addressing the issue of central effects of these drugs have been carried out. Often multiple therapies including a diuretic have been administered, with the primary purpose of the study to investigate effects of other drugs such asadrenoceptor antagonists and angiotensin converting enzyme inhibitors.
It has therefore been difficult to establish whether central effects occur with diuretics administered alone. Motor performance, reaction time and colour matching in baboons were unaffected by treatment with hydrochlorothiazide and triamterene [13] . Memory function in hypertensive patients receiving diuretic medication was similarly unchanged compared with normotensive data, in contrast with deficits related to methyldopa and propranolol treatment [14] . No changes in cognitive ability assessed by the Wechsler Adult Intelligence Scale were seen with furosemide administered to normotensive individuals [15] . Concomitant therapy with hydrochlorothiazide [16] did not affect cognitive performance and memory in patients treated with enalapril.
Nevertheless some studies have suggested the possibility of effects, although not with single agents. Hydrochlorothiazide and amiloride increased Type A behaviour characteristics, generally associated with greater risk of cardiovascular disease, while atenolol had the reverse effect [17] . Croog et al. [18] reported that hydrochlorothiazide modified the effects of captopril, propranolol and methyldopa on quality of life, where apparent improvements in well-being with captopril were attenuated by the diuretic.
The majority of investigations have involved multiple therapies and chronic drug ingestion in hypertensive patients, where confounding factors exist including changes with time and effects of hypertension. In the light of this, there appears to be little evidence for centrally mediated side effects with diuretics per se.
The present study involving acute ingestion of bendrofluazide in healthy volunteers has used a schedule of tests known to be sensitive to the central effects of drugs [1] [2] [3] [4] [5] . In view of the absence of change in the EEG and tests of attention and memory, a central effect of bendrofluazide is considered to be unlikely. The changes in body sway and psychomotor performance seen with bendrofluazide may be related to peripheral effects.
In conclusion, we have been unable to establish central effects with the diuretic, bendrofluazide, and there was no evidence of sedation or reduced vigilance. The present investigation is part of a programme of studies with healthy volunteers to identify the potential central effects of antihypertensive medication, in which we have previously demonstrated that angiotensin converting enzyme inhibitors and calcium antagonists are free of sedation and impaired psychomotor performance. Given the availability of such therapy, any adverse change in psychomotor performance with bendrofluazide irrespective of whether it is centrally or peripherally mediated should be considered when choosing therapy for individuals with mild hypertension who are engaged in skilled activities.
